1. Autophagy
  2. ULK


ULK1, a serine/threonine protein kinase, is an enzyme that in humans is encoded by the ULK1 gene. ULK1 is essential for the initial stages of autophagy. ULK1 is an important protein in autophagy. It is part of the ULK1-complex, which is needed in early steps of autophagosome biogenesis. ULK1 inhibition results in accumulation of stalled early autophagosomal structures, indicating a role for ULK1 in the maturation of autophagosomes as well as initiation.

ULK2 is essential for astrocyte transformation and tumor growth. ULK2 also inhibits the growth of glioma cells, which requires autophagy induction as kinase mutant of ULK2 fails to induce autophagy and inhibit growth. ULK2 and its homologue ULK1 are only down-regulated in all grades of glioma. Thus these results altogether suggest that inhibition of autophagy by ULK1/2 down-regulation is essential for glioma development.

ULK Related Products (9):

Cat. No. Product Name Effect Purity
  • HY-100006A
    MRT68921 dihydrochloride Inhibitor 99.38%
    MRT68921 dihydrochloride is a potent inhibitor of ULK1 and ULK2, with IC50 values of 2.9 nM and 1.1 nM, respectively[1].
  • HY-16966
    SBI-0206965 Inhibitor 98.88%
    SBI-0206965 is a potent, selective and cell permeable autophagy kinase ULK1 inhibitor with IC50s of 108 nM for ULK1 kinase and 711 nM for the highly related kinase ULK2[1].
  • HY-114490
    ULK-101 Inhibitor 99.98%
    ULK-101 is a potent and selective ULK1 inhibitor, with IC50 values of 1.6 nM and 30 nM for ULK1 and ULK2, respectively. ULK-101 suppresses autophagy and sensitizes cancer cells to nutrient stress[1].
  • HY-13018
    MRT67307 Inhibitor 99.34%
    MRT67307 is a dual inhibitor of the IKKε and TBK-1 with IC50s of 160 and 19 nM, respectively[1]. MRT67307 also inhibits ULK1 and ULK2 with IC50s of 45 and 38 nM, respectively. MRT67307 also blocks autophagy in cells[2].
  • HY-101923B
    LYN-1604 dihydrochloride Activator 98.73%
    LYN-1604 dihydrochloride is a potent UNC-51-like kinase 1 (ULK1) activator (EC50=18.94 nM) for the research of triple negative breast cancer (TNBC)[1].
  • HY-137742
    SBP-7455 Inhibitor
    SBP-7455 is a potent, high affinity and orally active dual ULK1/ULK2 autophagy inhibitor with IC50s of 13 nM and 476 nM in the ADP-Glo assays, respectively. SBP-7455 potently inhibits ULK1/2 enzymatic activity and can be used for triple-negative breast cancer (TNBC) research[1].
  • HY-115570
    GW406108X Inhibitor >98.0%
    GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC50 of 0.82 uM in ATPase assays. GW406108X, a potent autophagy inhibitor, shows ATP competitive inhibition against ULK1 with a pIC50 of 6.37 (427 nM). GW406108X inhibits ULK1 kinase activity and blocks autophagic flux, without affecting the upstream signaling kinases mTORC1 and AMPK[1][2].
  • HY-124729
    BL-918 Activator 98.36%
    BL-918 is an orally active UNC-51-like kinase 1 (ULK1) activator with an EC50 of 24.14 nM. BL-918 exerts its cytoprotective autophagic effect by targeting ULK complex. BL-918 has the potential for Parkinson’s disease (PD) treatment[1].
  • HY-124729A
    (Rac)-BL-918 Activator 98.03%
    (Rac)-BL-918 is the racemate of BL-918. BL-918 is a potent activator of UNC-51-like kinase 1 (ULK1), inducing cytoprotective autophagy for Parkinson’s disease treatment[1].